FDA approves topical treatment for junctional, dystrophic EB FDA approves topical treatment for junctional, dystrophic EB

This is the first approved treatment for wounds associated with JEB and the second for patients with DEB, following the approval of a topical gene therapy in May 2023.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology Source Type: news